POLICY PERSPECTIVE As we approach Independence Day this weekend during a COVID-19 pandemic that is resurgent in 37 of 50 of the United States we recognize that good health and good policy go hand in...
Throughout these past many months, we have all been working to stay safe, healthy, and up to date on all things COVID-19 related. The GLI team has been actively engaging with fellow advocacy groups,...
This week Global Liver Institute (GLI) submitted comments on the Institute for Clinical and Economic Review (ICER) draft evidence report entitled “Obeticholic Acid for the Treatment of Nonalcoholic...
The effects of the novel coronavirus pandemic on liver patients’ ability to access non-COVID-19 related care have been broad, and pervasive. The guidance for initiation of treatment and management...
We recently recognized National Doctor’s Day in the US and joined people from around the world to applaud and celebrate all medical professionals working in the trenches and on the frontlines of...
Either by the immunosuppressive nature of our conditions or as an effect of the medications we are taking, liver patients should be considered vulnerable and at high-risk for contracting a COVID-19...
The novel coronavirus pathogen known as “SARS-CoV-2” and the disease it causes, COVID-19 has infected enough people in enough countries to be declared by the World Health Organization (WHO),...
Donna Cryer sends letter to Secretary Alex Azar of HHS, and Aministrator Seema Verma of CMS In response to AOPO’s recent misinformation campaign, GLI sent this letter to HHS in support of the...
The HIV, Hepatitis, and Related Conditions Programs (HHRC) in the Veterans Health Administration (VA) is working to improve care for viral hepatitis and liver disease. The VA has seen many recent...
Rare Disease Day, celebrated across social media and IRL on the last day of the shortest month of the year, is a growing global movement, shining a light on the thousands of conditions cumulatively...
Recent News
Policy, Prevention, and Progress: Fatty Liver & Obesity Dr. Kelly Brownell, Dean Emeritus of the Sanford School of Public Policy at Duke University, has over 35 years of experience studying food systems and obesity. After initially focusing on obesity treatments,...
Perils of AI in Healthcare Donna Cryer, JD, and Deborah SobelAs the founder and CEO of Global Liver Institute (GLI), and a liver transplant patient myself, I know it is imperative to connect the dots between real-world experiences of patients and policy solutions....
From Awareness to Action on Global Fatty Liver Day Global Liver Institute Unites the Field in Times of Name Changes and New Treatments(Washington, DC - June 13, 2024) – Today marks the seventh annual Global Fatty Liver Day (formerly International NASH Day), led by...
GLI Celebrates with PBC Patient Community upon U.S. FDA’s Approval of Second-Line Treatment(Washington, D.C. June 10, 2024) – Global Liver Institute (GLI) celebrates the decision of the U.S. Food and Drug Administration (FDA) to provide accelerated approval to...
GLI responds to VA efforts to deny or delay access to NASH/MASH treatment while proactively pushing for Congress to advance policies that support access to comprehensive care for liver disease patients. Join Global Liver Institute to Push Congress to Advance Priority...
